晚期前列腺癌循环肿瘤DNA:从发现走向临床检测
综述指出转移性去势抵抗性前列腺癌(mCRPC)基因组异于原发瘤且随进展动态变化。血浆游离DNA中的循环肿瘤DNA(ctDNA)与转移灶活检基因组高度重叠,可无创、重复反映多转移灶。高灵敏度NGS与数字PCR已用于追踪AR异常和HRR基因改变;现有结果需前瞻性临床试验确认。
要点
- ctDNA与转移灶活检基因组高度重叠,可无创、连续反映多转移灶基因组。
- mCRPC中可追踪AR异常和HRR基因改变等具临床相关性的基因组变异。
- cfDNA分析有望用于预后、预测、疗效监测和耐药机制识别,尚待前瞻性验证。
核心结论
- ctDNA分析在mCRPC中已显示可用于追踪临床相关基因组变异,但结果仍需前瞻性临床试验确认。
- ctDNA与转移灶活检基因组序列高度重叠,且能代表多个转移灶。
- AR异常与新型抗雄激素治疗不良结局相关,HRR基因改变与PARP抑制剂应答相关。
研究设计与样本
- 综述,未报告系统检索范围与样本量。
- 讨论通过微创抽血获取血浆cfDNA中含ctDNA并进行序贯分析。
- 提及高灵敏度、高特异性的二代测序(NGS)与数字PCR技术。
主要发现
- mCRPC基因组图谱与原发肿瘤不同,并在肿瘤进展中动态变化。
- 常规实体瘤活检难以实时、重复表征该过程。
- ctDNA可在低ctDNA比例下检测基因组改变。
- 已提出cfDNA分析作为预后工具、预测性生物标志物、监测肿瘤应答和识别新耐药机制等临床应用。
临床怎么用
- mCRPC患者可通过血浆cfDNA分析追踪AR异常和HRR基因改变,辅助治疗决策与监测。
- 应用前应认识到现有证据多来自探索性研究,需前瞻性临床试验确认。
- NGS与数字PCR可用于低ctDNA比例下的基因组改变检测。
局限性
- 现有cfDNA分析结果虽有趣,但亟需前瞻性临床试验确认。
- 综述未报告检索范围、样本量及具体效应数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The genomic landscape of metastatic castration-resistant prostate cancer (mCRPC) differs from that of the primary tumor and is dynamic during tumor progression. The real-time and repeated characterization of this process via conventional solid tumor biopsies is challenging. Alternatively, circulating cell-free DNA (cfDNA) containing circulating tumor DNA (ctDNA) can be obtained from patient plasma using minimally disruptive blood draws and is amenable to sequential analysis. ctDNA has high overlap with the genomic sequences of biopsies from metastases and has the advantage of being representative of multiple metastases. The availability of techniques with high sensitivity and specificity, such as next-generation sequencing (NGS) and digital PCR, has greatly contributed to the development of the cfDNA field and enabled the detection of genomic alterations at low ctDNA fractions. In mCRPC, a number of clinically relevant genomic alterations have been tracked in ctDNA, including androgen receptor (AR) aberrations, which have been shown to be associated with an adverse outcome to novel antiandrogen therapies, and alterations in homologous recombination repair (HRR) genes, which have been associated with a response to PARP inhibitors. Several clinical applications have been proposed for cfDNA analysis, including its use as a prognostic tool, as a predictive biomarker, to monitor tumor response and to identify novel mechanisms of resistance. To date, the cfDNA analysis has provided interesting results, but there is an urgent need for these findings to be confirmed in prospective clinical trials.
引用
- González-Billalabeitia E, Conteduca V, Wetterskog D, et al. Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test. Prostate Cancer Prostatic Dis. 2018. PMID: 30413805. doi:10.1038/s41391-018-0098-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。